Yuxia Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuxia Zhao has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Lu Bai
Department of Radiation Oncology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
3 shared publicationsBaosen Zhou
Department of Epidemiology, China Medical University, Shenyang, Liaoning 110001, P.R. China
2 shared publicationsHe-Tong Wang
Department of Radiotherapy Oncology, The Fourth Hospital of China Medical University, Shenyang, Liaoning, China (mainland)
2 shared publicationsHetong Wang
2 shared publicationsHong Yu
Liaoning Canc Hosp & Inst, Dept Radiotherapy Oncol, Shenyang 110042, Peoples R China
2 shared publicationsHongxin Su
2 shared publications
Latest Publications
- 29 March 2021
- Published by Spandidos Publications in Oncology Letters
- Vol. 21 (5) , 1-7
Single nucleotide polymorphisms in breast cancer susceptibility gene 1 are associated with susceptibility to lung cancer
BRCA1 is a tumor suppressor that has been found to be involved DNA synthesis during cell replication. In a recent study, the single nucleotide polymorphism (SNP), rs799917, in BRCA1 was found to be associated with the development and progression of various types of tumor. In the present study, the association between rs799917 and susceptibility to lung cancer was evaluated in a Han Chinese population in the Liaoning Province of China. The BRCA1 rs799917 genotypes (C/C, C/T and T/T) were analyzed using TaqMan quantitative PCR in 682 patients with lung cancer and 694 healthy controls, and the results were analyzed using a Student's t‑test, a χ2 test and logistic regression analysis. Individuals carrying the C/T or T/T genotype had a lower risk of lung cancer compared with those carrying the C/C genotype [odds ratio (OR), 0.741; P=0.021; and OR, 0.610; P=0.011, respectively). The C/T + T/T genotype group had an even lower risk (OR, 0.709; P=0.005) compared with that in the C/C genotype group. In the stratified analyses of non‑smokers, individuals with the C/T or T/T genotype had a lower risk of developing lung cancer compared with that in those carrying the C/C genotype (OR, 0.681; P=0.013; and OR, 0.569; P=0.021, respectively). The stratified analyses of the BRCA1 rs799917 polymorphism based on pathological type, chemotherapy and radiotherapy, showed that in the squamous cell carcinoma, non‑chemotherapy and non‑radiotherapy subgroups, individuals with the T/T genotype had a lower risk of lung cancer compared with that in those carrying the C/C genotype (OR, 0.454; P=0.007; OR, 0.485; P=0.002; and OR, 0.599; P=0.020, respectively). In conclusion, the T allele of the rs799917 SNP in BRCA1 was associated with a lower risk of lung cancer in the ethnic Han Chinese population in Liaoning Province and may represent a protective factor against lung cancer.
- 29 March 2021
- Published by Spandidos Publications in Oncology Letters
- Vol. 21 (5) , 1-7
Single nucleotide polymorphisms in breast cancer susceptibility gene 1 are associated with susceptibility to lung cancer
BRCA1 is a tumor suppressor that has been found to be involved DNA synthesis during cell replication. In a recent study, the single nucleotide polymorphism (SNP), rs799917, in BRCA1 was found to be associated with the development and progression of various types of tumor. In the present study, the association between rs799917 and susceptibility to lung cancer was evaluated in a Han Chinese population in the Liaoning Province of China. The BRCA1 rs799917 genotypes (C/C, C/T and T/T) were analyzed using TaqMan quantitative PCR in 682 patients with lung cancer and 694 healthy controls, and the results were analyzed using a Student's t‑test, a χ2 test and logistic regression analysis. Individuals carrying the C/T or T/T genotype had a lower risk of lung cancer compared with those carrying the C/C genotype [odds ratio (OR), 0.741; P=0.021; and OR, 0.610; P=0.011, respectively). The C/T + T/T genotype group had an even lower risk (OR, 0.709; P=0.005) compared with that in the C/C genotype group. In the stratified analyses of non‑smokers, individuals with the C/T or T/T genotype had a lower risk of developing lung cancer compared with that in those carrying the C/C genotype (OR, 0.681; P=0.013; and OR, 0.569; P=0.021, respectively). The stratified analyses of the BRCA1 rs799917 polymorphism based on pathological type, chemotherapy and radiotherapy, showed that in the squamous cell carcinoma, non‑chemotherapy and non‑radiotherapy subgroups, individuals with the T/T genotype had a lower risk of lung cancer compared with that in those carrying the C/C genotype (OR, 0.454; P=0.007; OR, 0.485; P=0.002; and OR, 0.599; P=0.020, respectively). In conclusion, the T allele of the rs799917 SNP in BRCA1 was associated with a lower risk of lung cancer in the ethnic Han Chinese population in Liaoning Province and may represent a protective factor against lung cancer.
- 26 August 2020
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 147 (2) , 569-577
Brain metastases of lung cancer: comparison of survival outcomes among whole brain radiotherapy, whole brain radiotherapy with consecutive boost, and simultaneous integrated boost
Purpose Radiotherapy is the mainstay for treating brain metastasis (BM). The objective of this study is to evaluate the overall survival (OS) of patients with BM of lung cancer treated with different radiotherapy modalities. Methods Patients with BM of lung cancer who underwent radiotherapy between July 2007 and November 2017 were collected, and their baseline demographics, clinicopathological characteristics and treatments were recorded. Survival was estimated by the Kaplan–Meier method and compared by using the log-rank test. Univariate and multivariate analysis of the prognostic factors were performed using the Cox proportional hazard regression model. Results A total of 144 patients were enrolled, of whom 77 underwent whole-brain radiotherapy (WBRT), 39 underwent whole brain radiotherapy with consecutive boost (WBRT + boost), and 28 underwent integrated simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT). The OS in SIB-IMRT group was significantly longer than that in WBRT group (median OS 14 (95% confidence interval [CI] 8.8–19.1) vs.7 (95% CI 5.5–8.5) months, log-rank p < 0.001) and WBRT + boost group (median OS: 14 (95% CI 8.8–19.1) vs.11 (95% CI 8.3–13.7) months, log-rank p = 0.037). Multivariable analysis showed that mortality risk of patients treated with SIB-IMRT decrease by 56, 59, 64 and 64% in unadjusted model (hazard ratio [HR] = 0.44; 95% CI 0.28–0.70, p < 0.001), model 1 (HR = 0.41; 95% CI 0.26–0.65, p < 0.001), model 2 (HR = 0.36; 95% CI 0.21–0.61, p < 0.001), and model 3 (HR = 0.36; 95% CI 0.21–0.61, p < 0.001). Conclusions For patients with BM of lung cancer, SIB-IMRT seems to be associated with a more favorable prognosis.
- 26 August 2020
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 147 (2) , 569-577
Brain metastases of lung cancer: comparison of survival outcomes among whole brain radiotherapy, whole brain radiotherapy with consecutive boost, and simultaneous integrated boost
Purpose Radiotherapy is the mainstay for treating brain metastasis (BM). The objective of this study is to evaluate the overall survival (OS) of patients with BM of lung cancer treated with different radiotherapy modalities. Methods Patients with BM of lung cancer who underwent radiotherapy between July 2007 and November 2017 were collected, and their baseline demographics, clinicopathological characteristics and treatments were recorded. Survival was estimated by the Kaplan–Meier method and compared by using the log-rank test. Univariate and multivariate analysis of the prognostic factors were performed using the Cox proportional hazard regression model. Results A total of 144 patients were enrolled, of whom 77 underwent whole-brain radiotherapy (WBRT), 39 underwent whole brain radiotherapy with consecutive boost (WBRT + boost), and 28 underwent integrated simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT). The OS in SIB-IMRT group was significantly longer than that in WBRT group (median OS 14 (95% confidence interval [CI] 8.8–19.1) vs.7 (95% CI 5.5–8.5) months, log-rank p < 0.001) and WBRT + boost group (median OS: 14 (95% CI 8.8–19.1) vs.11 (95% CI 8.3–13.7) months, log-rank p = 0.037). Multivariable analysis showed that mortality risk of patients treated with SIB-IMRT decrease by 56, 59, 64 and 64% in unadjusted model (hazard ratio [HR] = 0.44; 95% CI 0.28–0.70, p < 0.001), model 1 (HR = 0.41; 95% CI 0.26–0.65, p < 0.001), model 2 (HR = 0.36; 95% CI 0.21–0.61, p < 0.001), and model 3 (HR = 0.36; 95% CI 0.21–0.61, p < 0.001). Conclusions For patients with BM of lung cancer, SIB-IMRT seems to be associated with a more favorable prognosis.
- 1 April 2020
- Published by Elsevier in Experimental Cell Research
- Vol. 389 (2) , 111884
RALY may cause an aggressive biological behavior and a dismal prognosis in non-small-cell lung cancer
- 1 April 2020
- Published by Elsevier in Experimental Cell Research
- Vol. 389 (2) , 111884
RALY may cause an aggressive biological behavior and a dismal prognosis in non-small-cell lung cancer
- Open Access
- 2 August 2018
- Published by Springer Nature in BMC Medical Genetics
- Vol. 19 (1) , 136
Association between H19 SNP rs217727 and lung cancer risk in a Chinese population: a case control study
H19 was the first long non-coding RNA (lncRNA) to be confirmed. Recently, studies have suggested that H19 may participate in lung cancer (LC) development and progression. This study assessed whether single nucleotide polymorphisms (SNPs) in H19 are associated with the risk of LC in a Chinese population. A case-control study was performed, and H19 SNP rs217727 was analyzed in 555 lung cancer patients from two hospitals and 618 healthy controls to test the association between this SNP and the susceptibility to LC. The A/A homozygous genotype of rs217727 was significantly associated with an increased LC risk (odds ratio (OR) = 1.661, 95% confidence interval (CI) = 1.155 to 2.388, P = 0.006). Significant associations remained after stratification by smoking status (P < 0.001). Furthermore, the A/A genotype had a higher risk of LC than those of G/G in the squamous cell carcinoma (OR = 2.022, P = 0.004) and adenocarcinoma (OR = 1.606, P = 0.045) subgroups. The rs217727 SNP in lncRNA H19 was significantly associated with susceptibility to LC, particularly in squamous cell carcinoma and adenocarcinoma, and identified the homozygous A/A genotype as a risk factor for LC.
- 2 August 2018
- Published by Springer Nature in BMC Medical Genetics
- Vol. 19 (1) , 136
Open AccessAssociation between H19 SNP rs217727 and lung cancer risk in a Chinese population: a case control study
H19 was the first long non-coding RNA (lncRNA) to be confirmed. Recently, studies have suggested that H19 may participate in lung cancer (LC) development and progression. This study assessed whether single nucleotide polymorphisms (SNPs) in H19 are associated with the risk of LC in a Chinese population. A case-control study was performed, and H19 SNP rs217727 was analyzed in 555 lung cancer patients from two hospitals and 618 healthy controls to test the association between this SNP and the susceptibility to LC. The A/A homozygous genotype of rs217727 was significantly associated with an increased LC risk (odds ratio (OR) = 1.661, 95% confidence interval (CI) = 1.155 to 2.388, P = 0.006). Significant associations remained after stratification by smoking status (P < 0.001). Furthermore, the A/A genotype had a higher risk of LC than those of G/G in the squamous cell carcinoma (OR = 2.022, P = 0.004) and adenocarcinoma (OR = 1.606, P = 0.045) subgroups. The rs217727 SNP in lncRNA H19 was significantly associated with susceptibility to LC, particularly in squamous cell carcinoma and adenocarcinoma, and identified the homozygous A/A genotype as a risk factor for LC.
- Open Access
- 23 February 2017
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 23, 984-993
Association of Topoisomerase II (TOP2A) and Dual-Specificity Phosphatase 6 (DUSP6) Single Nucleotide Polymorphisms with Radiation Treatment Response and Prognosis of Lung Cancer in Han Chinese
BACKGROUND:Mutations of DNA topoisomerase II (TOP2A) are associated with chemotherapy resistance, whereas dual-specificity phosphatase 6 (DUSP6) negatively regulates members of the mitogen-activated protein (MAP) kinase superfamily to control cell pr...
- 23 February 2017
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 23, 984-993
Open AccessAssociation of Topoisomerase II (TOP2A) and Dual-Specificity Phosphatase 6 (DUSP6) Single Nucleotide Polymorphisms with Radiation Treatment Response and Prognosis of Lung Cancer in Han Chinese
BACKGROUND:Mutations of DNA topoisomerase II (TOP2A) are associated with chemotherapy resistance, whereas dual-specificity phosphatase 6 (DUSP6) negatively regulates members of the mitogen-activated protein (MAP) kinase superfamily to control cell pr...
- 1 January 2016
- Published by Clinical Laboratory Publications in Clinical Laboratory
- Vol. 62 (03/2016) , 301-310
Dual Specificity Phosphatase 6 (DUSP6) Polymorphism Predicts Prognosis of Inoperable Non-Small Cell Lung Cancer after Chemoradiotherapy
Background: Dual-specificity phosphatase 6 (DUSP6) inactivates different target kinases to regulate cell proliferation and differentiation. Altered DUSP6 expressions or gene polymorphisms are associated with human cancer development including non-small cell lung cancer (NSCLC). DNA topoisomerase II alpha (TOP2A) regulates chromosome condensation and chromatid separation, and altered TOP2A expressions are associated with drug resistance development. This study assessed DUSP6 and TOP2A single nucleotide polymorphisms (SNPs) associated with NSCLC patient survival. Methods: This study included 152 surgically resected NSCLC patients and 277 chemoradiotherapy treated inoperable cases. DNA samples from each patient were genotyped for DUSP6 and TOP2A SNPs. Kaplan-Meier survival analysis, log-rank test, and Cox proportional hazard model were used to evaluate the association between these variants and NSCLC overall survival. Results: DUSP6 rs2279574 A/A genotype was associated with significantly poor inoperable NSCLC patient overall survival (A/A vs. C/C, adjusted HR = 1.549, 95% CI = 1.019 - 2.355). Stratification analysis against clinical stage, histology, weight loss, and ECOG performance status revealed that the DUSP6 rs2279574 A/A variant homozygous genotype is associated with a decrease in survival of stage IV NSCLC patients compared to those with the C/C genotype (log-rank, p = 0.003). No association was found among histology, weight loss, and ECOG performance status. Moreover, there was no association of TOP2A SNPs between clinicopathological and survival data. Conclusions: Data obtained from the current study demonstrated that functional DUSP6 rs2279574 polymorphism was able to predict inoperable NSCLC patient survival after chemoradiotherapy.
- 1 January 2016
- Published by Clinical Laboratory Publications in Clinical Laboratory
- Vol. 62 (03/2016) , 301-310
Dual Specificity Phosphatase 6 (DUSP6) Polymorphism Predicts Prognosis of Inoperable Non-Small Cell Lung Cancer after Chemoradiotherapy
Background: Dual-specificity phosphatase 6 (DUSP6) inactivates different target kinases to regulate cell proliferation and differentiation. Altered DUSP6 expressions or gene polymorphisms are associated with human cancer development including non-small cell lung cancer (NSCLC). DNA topoisomerase II alpha (TOP2A) regulates chromosome condensation and chromatid separation, and altered TOP2A expressions are associated with drug resistance development. This study assessed DUSP6 and TOP2A single nucleotide polymorphisms (SNPs) associated with NSCLC patient survival. Methods: This study included 152 surgically resected NSCLC patients and 277 chemoradiotherapy treated inoperable cases. DNA samples from each patient were genotyped for DUSP6 and TOP2A SNPs. Kaplan-Meier survival analysis, log-rank test, and Cox proportional hazard model were used to evaluate the association between these variants and NSCLC overall survival. Results: DUSP6 rs2279574 A/A genotype was associated with significantly poor inoperable NSCLC patient overall survival (A/A vs. C/C, adjusted HR = 1.549, 95% CI = 1.019 - 2.355). Stratification analysis against clinical stage, histology, weight loss, and ECOG performance status revealed that the DUSP6 rs2279574 A/A variant homozygous genotype is associated with a decrease in survival of stage IV NSCLC patients compared to those with the C/C genotype (log-rank, p = 0.003). No association was found among histology, weight loss, and ECOG performance status. Moreover, there was no association of TOP2A SNPs between clinicopathological and survival data. Conclusions: Data obtained from the current study demonstrated that functional DUSP6 rs2279574 polymorphism was able to predict inoperable NSCLC patient survival after chemoradiotherapy.
- 1 January 2015
- Vol. 61 (7)
Survival and Prognostic Analysis of Primary Nasopharyngeal Carcinoma in North China.
- 1 January 2015
- Vol. 61 (7)
Survival and Prognostic Analysis of Primary Nasopharyngeal Carcinoma in North China.
- Open Access
- 24 February 2014
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 55 (4) , 683-689
The expression of aquaporins 1 and 5 in rat lung after thoracic irradiation
Radiation-induced lung toxicity (RILT), leading to radiation pneumonia or fibrosis, is a primary problem of radiation therapy. The pathogenesis of RILT remains unclear. In this study, we used a rat model of RILT to examine the expression of aquaporins (AQPs) after radiation injury. Sprague Dawley rats were given a single dose of 17 Gy (dose rate of 3.0 Gy/min) of X-irradiation to the thorax. Rats that survived acute pneumonitis (at 1–4 weeks) were evaluated weekly for the expression of AQP1 and AQP5 in the lung by immunohistochemical and reverse transcription polymerase chain reaction (RT-PCR) analyses. Immunohistochemical analysis showed that AQP1 protein was expressed in the capillary endothelium, and its level was significantly decreased after irradiation. AQP5 protein was expressed in the alveolar epithelium, and its level was increased between Days 7 and 14 after irradiation but decreased at Day 28, compared with the sham group. The RT-PCR results were consistent with the immunohistochemical analysis results. In summary, this study provides the first report of AQP1 and AQP5 expression in a model of radiation-induced pulmonary inflammation and edema. Decreased levels of AQP1 and AQP5 after irradiation suggest that these proteins play a role in the pathogenesis of RILT.
- 24 February 2014
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 55 (4) , 683-689
Open AccessThe expression of aquaporins 1 and 5 in rat lung after thoracic irradiation
Radiation-induced lung toxicity (RILT), leading to radiation pneumonia or fibrosis, is a primary problem of radiation therapy. The pathogenesis of RILT remains unclear. In this study, we used a rat model of RILT to examine the expression of aquaporins (AQPs) after radiation injury. Sprague Dawley rats were given a single dose of 17 Gy (dose rate of 3.0 Gy/min) of X-irradiation to the thorax. Rats that survived acute pneumonitis (at 1–4 weeks) were evaluated weekly for the expression of AQP1 and AQP5 in the lung by immunohistochemical and reverse transcription polymerase chain reaction (RT-PCR) analyses. Immunohistochemical analysis showed that AQP1 protein was expressed in the capillary endothelium, and its level was significantly decreased after irradiation. AQP5 protein was expressed in the alveolar epithelium, and its level was increased between Days 7 and 14 after irradiation but decreased at Day 28, compared with the sham group. The RT-PCR results were consistent with the immunohistochemical analysis results. In summary, this study provides the first report of AQP1 and AQP5 expression in a model of radiation-induced pulmonary inflammation and edema. Decreased levels of AQP1 and AQP5 after irradiation suggest that these proteins play a role in the pathogenesis of RILT.
- 1 January 2014
- Published by Elsevier in Archives of Medical Research
- Vol. 45 (1) , 84-89
Common Genetic Variants in 53BP1 Associated with Nonsmall-cell Lung Cancer Risk in Han Chinese
- 1 January 2014
- Published by Elsevier in Archives of Medical Research
- Vol. 45 (1) , 84-89
Common Genetic Variants in 53BP1 Associated with Nonsmall-cell Lung Cancer Risk in Han Chinese
- 6 January 2013
- Published by Springer Nature in Medical Oncology
- Vol. 30 (1) , 414
Genetic single-nucleotide polymorphisms of inflammation-related factors associated with risk of lung cancer
This study was to investigate the association of inflammation-related factors with the risk of lung cancer. All subjects were unrelated ethnic Han Chinese in Liaoning province. Our study conducted a hospital-based case–control study, the case group consisted of 193 histologically diagnosed lung cancer patients, and 211 controls were selected from cancer-free patients at the same. 5 single-nucleotide polymorphisms (TGFβ1 +869T/C, IL6 −634C/G, TGFβ1 −509C/T, IL1β −511C/T, and IL1α −899C/T) in inflammatory genes (IL1, IL6, TGF) were analyzed by Taqman real-time PCR method. All statistical analyses were performed with statistical product and service solutions v13.0. The genotype distribution frequency of IL6 −634C/G exists significant difference between case and control group. Individuals carrying −634GG and CG genotype had a higher risk of lung cancer. The risk allele was G in IL6 −634C/G.
- 6 January 2013
- Published by Springer Nature in Medical Oncology
- Vol. 30 (1) , 414
Genetic single-nucleotide polymorphisms of inflammation-related factors associated with risk of lung cancer
This study was to investigate the association of inflammation-related factors with the risk of lung cancer. All subjects were unrelated ethnic Han Chinese in Liaoning province. Our study conducted a hospital-based case–control study, the case group consisted of 193 histologically diagnosed lung cancer patients, and 211 controls were selected from cancer-free patients at the same. 5 single-nucleotide polymorphisms (TGFβ1 +869T/C, IL6 −634C/G, TGFβ1 −509C/T, IL1β −511C/T, and IL1α −899C/T) in inflammatory genes (IL1, IL6, TGF) were analyzed by Taqman real-time PCR method. All statistical analyses were performed with statistical product and service solutions v13.0. The genotype distribution frequency of IL6 −634C/G exists significant difference between case and control group. Individuals carrying −634GG and CG genotype had a higher risk of lung cancer. The risk allele was G in IL6 −634C/G.